This compound belongs to a class of metabolic regulators often examined alongside NAD+ pathway research
These approaches have led to significant weight loss with the dual GLP-1/glucagon receptor agonist survodutide (-13.5% with the 6-mg dose at 76 weeks in a phase 3 SYNCHRONIZE-1 trial) [16] , the dual GLP-1 receptor agonist and GIP antagonist Maridebart cafraglutide (known as MariTide) (-12.3% to -16.2% across different doses at 52 weeks in a phase 2 trial) [17] or the triple GLP-1/GIP/glucagon receptor agonist retatrutide (-24.2% with the 12-mg dose at 48 weeks in a phase 2 trial) [18]
Through analysis of fecal samples and functional magnetic resonance imaging data from 23 MDD patients, the study determined that the relative abundance of fecal Bacteroides was significantly negatively correlated with functional connectivity in depression-related brain regions ( r = 0.67, P = 0.0005)
However, orforglipron: Provides double-digit weight loss Works without needles or refrigeration May improve long-term adherence compared with weekly injections This places it among the most promising oral GLP-1 options currently in late-stage development
Exact timing depends on the medication and how your body responds to it
IcoSema could be a true game-changer, as it would further reduce the number of injections to just 52 per year
